Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy

Cancer Research

Volumn 60, Issue 17, 2000, Pages 4812-4818

  Nutt, C L ^a   Noble, M ^a   Chambers, A F ^a   Cairncross, J G ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 O BENZYLGUANINE; BUTHIONINE SULFOXIMINE; CARMUSTINE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MULTIDRUG RESISTANCE PROTEIN; PROTEIN P53;

ANIMAL CELL; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL DIFFERENTIATION; CHEMOSENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GLIA CELL; GLUTATHIONE METABOLISM; IMMUNOCYTOCHEMISTRY; NEWBORN; NONHUMAN; OLIGODENDROGLIOMA; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASTROCYTES; ASTROCYTOMA; ATP-BINDING CASSETTE TRANSPORTERS; CARMUSTINE; CELL DEATH; CELL LINEAGE; CRICETINAE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; ISOENZYMES; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGODENDROGLIA; OLIGODENDROGLIOMA; RATS; RATS, SPRAGUE-DAWLEY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034282996     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Successful chemotherapy for recurrent malignant oligodendroglioma
2. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma
3. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy
4. Aggressive oligodendroglioma: A chemosensitive tumor
5. Chemotherapy for anaplastic oligodendroglioma
6. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas
7. Low-grade oligodendroglioma responds to chemotherapy
8. Prognostic significance of glutathione S-transferase π expression and subcellular localization in human gliomas
9. Role of oncogenes in resistance and killing by cancer therapeutic agents
10. The chemoresistance of human malignant melanoma: An update
11. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
12. Specific carcinogenic and teratogenic effects of 'indirect' alkylating methyl and ethyl compounds, and their dependency on stages of ontogenic developments
13. Selective induction by N-nitrosoethylurea of oligodendrogliomas in fetal forebrain transplants
14. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial
15. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
16. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas
17. 6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis
18. Regulation and expression of the adaptive response to alkylating agents
19. 6-alkylguanine-DNA transferases
20. 6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents
21. 6-alkylguanine DNA repair activity during continuous exposure to carcinogen
22. 6-methylguanine
23. 6-alkylguanines increases sensitivity to the cytotoxic effects of alkylating agents
24. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents
25. 6-methylguanine-DNAmethyltransferase (MGMT) cDNA in Chinese hamster cells: The role of MGMT in protection against the genotoxic effects of alkylating agents
26. The roles of intracellular glutathione in antineoplastic chemotherapy
27. Pharmacology of cancer chemotherapy. Section II: Mechanisms of drug resistance
28. Nomenclature for human glutathione transferases
29. Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione
30. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion
31. Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines
32. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion
33. Reduction in cellular glutathione by buthionine sulfoximine and sensitization of murine tumor cells resistant to L-phenylalanine mustard
34. Glutathione-conferred resistance to antineoplastics: Approaches toward its reduction
35. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs
36. Rat neural antigen-2 (RAN-2): A cell surface antigen on astrocytes, ependymal cells, Muller cells and lepto-meninges defined by a monoclonal antibody
37. Monoclonal antibody to a plasma membrane antigen of neurons
38. Development of oligodendrocytes and Schwann cells studied with a monoclonal antibody against galactocerebroside
39. Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue
40. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro
41. Growth of a rat neuroblastoma cell line in serum-free supplemented medium
42. Type-2 astrocyte development in rat brain cultures is initiated by a CNTF-like protein produced by type-1 astrocytes
43. Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells
44. Identification of members of the P-glycoprotein multigene family
45. Molecular Cloning
46. 6-Methylguanine-DNA methyltransferase activity, p53 gene status, and BCNU resistance in mouse astrocytes
47. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)
48. Assessment of the role of the glutathione and pentose phosphate pathways in the protection of primary cerebrocortical cultures from oxidative stress
49. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay
50. Alternatively spliced p53 RNA in transformed and normal cells of different tissue types
51. Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53
52. Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cell lines by a transacting transcriptional repressor
53. 6-Methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage
54. Low glutathione and high iron govern the susceptibility of oligodendroglial precursors to oxidative stress
55. Plastic phenotype of human oligodendroglial tumour cells in vitro
56. The NG2 chondroitin sulfate proteoglycan: A multifunctional proteoglycan associated with immature cells
57. Expression of oligodendrocyte progenitor cell antigens by gliomas: Implications for the histogenesis of brain tumors
58. 6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study
59. 6-Methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics